AIRNA Announces First Patient Dosed in Phase 1 Trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Cambridge, MA, April 7, 2026 – AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, today announced the first patient has been dosed in the global Phase 1 clinical trial of AIR-001, AIRNA’s potential best-in-class RNA-editing candidate for the treatment of alpha-1 antitrypsin deficiency (AATD). “RNA […] The post AIRNA Announces First Patient Dosed in Phase 1 Trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) appeared first on Airna .